Evidence map›Paper›PMID 37816857›Full record

ArticleActa pharmacologica Sinica2024

A dual role of lysophosphatidic acid type 2 receptor (LPAR2) in nonsteroidal anti-inflammatory drug-induced mouse enteropathy.

Barbara Hutka, Anett Várallyay, Szilvia B László, András S Tóth, Bálint Scheich, Sándor Paku, Imre Vörös, Zoltán Pós, Zoltán V Varga, Derek D Norman and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Barbara HutkaDepartment of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
Anett VárallyayDepartment of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
Szilvia B LászlóDepartment of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
András S TóthDepartment of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
Bálint ScheichDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Sándor PakuDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Imre VörösDepartment of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
Zoltán PósDepartment of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary.
Zoltán V VargaDepartment of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
Derek D NormanDepartment of Physiology, College of Medicine, University of Tennessee Health Science Center (UTHSC), Memphis, TN, USA.
Andrea BaloghInstitute of Translational Medicine, Semmelweis University, Budapest, Hungary.
Zoltán BenyóInstitute of Translational Medicine, Semmelweis University, Budapest, Hungary.
Gábor TigyiDepartment of Physiology, College of Medicine, University of Tennessee Health Science Center (UTHSC), Memphis, TN, USA.
Klára GyiresDepartment of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
Zoltán S ZádoriDepartment of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary. zadori.zoltan@semmelweis.hu.
Semmelweis University · HUUniversity of Tennessee Health Science Center · USGedeon Richter (Hungary) · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lysophosphatidic acid (LPA) is a bioactive phospholipid mediator that has been found to ameliorate nonsteroidal anti-inflammatory drug (NSAID)-induced gastric injury by acting on lysophosphatidic acid type 2 receptor (LPAR2). In this study, we investigated whether LPAR2 signaling was implicated in the development of NSAID-induced small intestinal injury (enteropathy), another major complication of NSAID use. Wild-type (WT) and Lpar2 deficient (Lpar2

Indexed as

Diabetes Mellitus, Type 2Intestinal DiseasesLysophospholipidsAnimalsAnti-Inflammatory Agents, Non-SteroidalIndomethacinMiceMice, Inbred NODMice, SCIDReceptors, Lysophosphatidic AcidAnti-Inflammatory Agents, Non-SteroidalIndomethacinLpar2 protein, mouselysophosphatidic acidLysophospholipidsReceptors, Lysophosphatidic AcidautotaxinDBIBBenteropathyLPAR2lysophosphatidic acidnonsteroidal anti-inflammatory drug

Identifiers

PMID37816857
PMCPMC10789874
OpenAlexW4387502601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.